HopeStage
Back to all studies
WithdrawnNCT04311294

Development of a Selective ALDH2 Inhibitor to Treat AUD

Medication studyAges 21+United StatesAddiction
The study in practice

Understand this study

Who could participate?

Listed age limits: from 21 years.

Listed locations
Los AngelesSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateEstimated: April 2020
Recruitment status
Withdrawn
Enrollment listed in the registry
0
Sponsor
University of California, Los Angeles
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
Over 21 Years
Official registry ID
NCT04311294
Official title
Show the full official title

Development of a Selective ALDH2 Inhibitor for the Treatment of Alcohol Use Disorder

Recruitment & locations

Withdrawn

Los Angeles

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of California, Los Angeles, a university.

Does this study involve medication?

Yes. The study involves medication, including ANS-6637 Low Dose, ANS-6637 High Dose and Matched Placebo.

Who can participate?

Listed age limits: from 21 years.

Is this study still recruiting?

The registry lists this study as withdrawn.

Want to explore more studies?

Explore studies